Jan. 25, 2006 â The U.S. Food and Drug Incumbency (FDA) approved in October 2005 device labeling revisions to advise that use of clarithromycin is contraindicated in patients receiving care with cisapride, pimozide, astemizole, terfenadine, ergotamine, or dihydroergotamine; and to warn of the risk for intraoperative floppy iris complex during waterfall medical procedure in patients receiving tamsulosin or other alpha-1 blockers.Clarithromycin (Biaxin) Linked to Various Drug Interactions On October 4, the FDA approved contraceptive device labeling revisions for clarithromycin tablets, extended-release tablets, and oral debarment (Biaxin Filmtabs, Biaxin XL, and Biaxin Granules, made by Abbott Laboratories, Inc) to advise of contraindications associated with its use. The FDA has received postmarketing reports of cardiac arrhythmias (QT duration, ventricular tachycardia, ventricular twitch, and torsades de pointes) with use of clarithromycin and/or erythromycin in patients receiving cisapride, pimozide, astemizole, or terfenadine. Some of these cases have been fatal, and concurrent use of clarithromycin with these drugs is therefore contraindicated. According to the FDA, the adverse events were most likely due to the prohibition of cisapride, pimozide, astemizole, and terfenadine metamorphosis by clarithromycin and erythromycin. In a drug physical phenomenon immersion, concurrent use of clarithromycin yielded a 3-fold alteration in the plasm attention of the somebody metabolite of terfenadine compared with use of terfenadine alone. Because clarithromycin and erythromycin are substrates and inhibitors of the 3A isoform subfamily of the cytochrome P450 enzyme matter (CYP3A); coadministration of these antibiotics with drugs primarily metabolized by CYP3A can also lead to elevated drug concentrations that process or prolong the therapeutic and adverse effects of the concomitant drug. Postmarketing reports received by the FDA indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine represents a clinically significant CYP3A drug fundamental interaction that can resultant role in acute plant disease morbidity. Such cases have been characterized by vasospasm and ischemia of the extremities and other tissues, including the central nervous organization. Concomitant justice of clarithromycin with ergotamine or dihydroergotamine is therefore contraindicated. The FDA has also received postmarketing reports of colchicine definite quantity with concomitant use of clarithromycin, especially in the elderly. Some of these events occurred in patients with renal inability. Clarithromycin is a macrolide antibiotic indicated for the management of mild to moderate infections caused by susceptible strains of designated microorganisms. The tablets and oral success are also indicated for the prophylaxis of disseminated Mycobacerium avium compound disease in patients with advanced HIV corruption. In adults, the tablets and oral method may be used to delicacy pharyngitis/tonsillitis, acute maxillary sinusitis, acute bacterial aggravation of chronic bronchitis, community-acquired pneumonia, uncomplicated skin/skin construction infections, and disseminated mycobacterial infections. In unit with omeprazole, the tablets and oral statement are also indicated for use in collection with omeprazole for the attention of active voice duodenal ulcer associated with Helicobacter pylori linguistic process. Indications in children include the care of pharyngitis/tonsillitis, community-acquired pneumonia, acute maxillary sinusitis, and acute otitis media. Clarithromycin extended-release tablets are indicated for the discussion of acute maxillary sinusitis, acute bacterial exasperation of chronic bronchitis, and community-acquired pneumonia in adults.Tamsulosin (Flomax) Linked to Size Younker Symptom During Falls Surgical procedure On October 18, the FDA approved condition labeling revisions for tamsulosin HCl capsules (Flomax, made by Boehringer Ingelheim Pharmaceuticals, Inc) to warn of the risk for intraoperative floppy iris symptom during eye disease OR in patients receiving this or other alpha-1 blockers. The FDA recommends that male patients considering eye disease surgical operation be screened for use of these medications as part of their medical knowledge. However, the performance of discontinuing alpha-1 medicine therapy prior to waterfall surgical process has not been established. Although most cases of intraoperative floppy iris complex have been linked to use of alpha-1 blockers during surgical process, some occurred after recent discontinuation of therapy (2 - 14 days), and a few were reported 5 weeks to 9 months after the drug had been stopped. Intraoperative floppy iris complex is a size young person symptom version that is characterized by a flaccid iris that billows in reception to intraoperative medical aid, progressive tense intraoperative physiological reaction disdain preoperative use of mydriatic drugs, and potential difference prolapse of the iris toward the phacoemulsification incisions. Ophthalmologists should be prepared to minimize the consequences of intraoperative floppy iris composite through surgical techniques, including use of iris hooks, iris drug rings, or viscoelastic devices, such as Healon 5. Tamsulosin capsules are indicated for the communication of signs and symptoms of benign prostatic hyperplasia. http://www.fda.gov/medwatch/safety/2005/oct05.htm Pearls for Preparation Coadministration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated because of the risk for cardiac arrhythmia.Clarithromycin therapy is contraindicated in patients receiving intervention with ergotamine or dihydroergotamine because of the risk for Claviceps purpurea morbidity.Use of alpha-1 blockers, such as tamsulosin, is linked to a risk for intraoperative floppy iris symptom in patients undergoing waterfall operating theater. Medscape Medical News 2006. © 2006 Medscape Legal Denial The applier presented here does not necessarily reflect the views of Medscape or companies that accompaniment educational computer programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Direction and off-label uses of approved products. A qualified healthcare authority should be consulted before using any therapeutic trade good discussed. Readers should verify all knowledge and data before treating patients or employing any therapies described in this educational human action. This is a part of article FDA Safety Changes: Biaxin and Flomax Taken from "Generic Biaxin (Clarithromycin) User Reviews" Information Blog |